SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

by Ysios Capital

PRODYGY is a Phase I/II study to assess the safety, tolerability, efficacy and quality of life following a single subretinal injection of SPVN06 in the worst-seeing eye of adult patients with RP due t...

Read more

First clinical trial of a new drug to improve the cognitive function of people with Down syndrome

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

The Hospital del Mar Medical Research Institute is leading the study that will evaluate whether a new molecule can be used to improve the cognitive performance of people with Down syndrome.

Read more

Next generation SERD camizestrant significantly improves progession-free survival vs fulvestran in advanced ER+ HER2- breast cancer

by VHIO

Findings show that camizestrant, an oral next generation selective estrogen receptor degrader (ngSERD), significantly improves progression-free survival versus fulvestrant in patients with estrogen re...

Read more

La convergencia en la industria sanitaria: invertir en innovación y tecnología

by Asebio

En los últimos dos años hemos vivido una transformación en la industria sanitaria, viendo como dos grandes industrias, independientes y en constante evolución, se acercaban hasta acabar convergien...

Read more

Investigadores de INCLIVA, en colaboración con el Hospital General y el Hospital La Fe, muestran que el tratamiento con genisteína podría retrasar la aparición de demencia en pacientes con Alzheimer

by INCLIVA

El ensayo clínico GENIAL ha evaluado en humanos la eficacia de un suplemento con genisteína, un polifenol presente en la soja con efectos beneficiosos frente a enfermedades degenerativas

Read more

ORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-line treatment of iadademstat and azacitidine in oral presentation at ASH-2022

by Oryzon Genomics

Oryzon Genomics presents the final data from its Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the...

Read more

Pulmobiotics receives 1.9m euros to develop ‘living medicine’ for lung cancer

by Centre for Genomic Regulation

Researchers at Pulmobiotics, a start-up founded in 2020 at the Centre for Genomic Regulation (CRG) in Barcelona, have begun work on a ‘living medicine’ to improve the efficacy of lung cancer treat...

Read more

ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches al-immunotherapy

by Oryzon Genomics

Oryzon Genomics, S.A., announced today the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project (Breaking immune Resistance of Advanced cancers by HERV...

Read more

Recent studies show that MSC-1 LIF blokade is safe and well tolerated in patiens with advanced solid and point to LIF as a novel drug targen in inmune-oncology

by VHIO

The mission of the new drug is to block the LIF protein that is altered in various types of cancer, promoting the proliferation of tumor stem cells and deactivating the immune system's response agains...

Read more

Nace NoctuRNA Therapeutics, una spin-off de la UPF que desarrolla nuevos antivirales, basados ​​en una plataforma de ARN

by UPF - Universitat Pompeu Fabra

La nueva sociedad tiene por objetivo desarrollar, producir y comercializar una innovadora plataforma de fármacos basada en ARNs circulares artificiales (circRNAs) que permitirá la generación de nue...

Read more

Cómo transformar el desarrollo de nuevos fármacos con gemelos digitales de corazón

by Asebio

Corify Care y GENESIS Biomed desarrollarán una plataforma tecnológica que utiliza mapeo no-invasivo, modelos matemáticos de corazón e inteligencia artificial para predecir efectos secundarios de l...

Read more

Praseltinib demuestra su eficacia en cánceres con mutacion RET independientemente del tipo de tumor

by VHIO

Los nuevos datos del ensayo de fase 1/2 ARROW, en el que ha participado la Dra. Elena Garralda, directora de la Unidad de Terapia Molecular del Cáncer (UITM) – CaixaResearch del Vall d’Hebron Ins...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un ensayo de microscopía dinámica del ...

by CSIC - Centro Superior de Investigaciones Científicas

La revista ‘Nature Protocols’ selecciona esta técnica como “pro...

Photos Stream